The link between multidisciplinary team (MDT) care and better outcomes for lung cancer patients is virtually undisputed, but access to effective wrap around care can differ across oncology centres, countries and regions. The new report, Optimising multi-disciplinary/ tumour board care, examines the benefits of, and existing barriers to, MDT care in lung cancer.
An MDT refers to the coordination of health and care professionals who frequently meet to develop, manage and review treatment plans to best meet the needs of an individual patient.i Consensus continues to grow on the importance of this coordinated approach, however, equitable access to such treatment and care varies around the world due to barriers like time constraints, lack of support, logistical issues, staff shortages and geographic disparities – all of which can lead to suboptimal care provision.ii
In a new report, the Lung Ambition Alliance and its newly established Ambition, Improvement, Measurement (AIM) programme have collected insights spanning the lung cancer care pathway – from stakeholders including clinicians, patient groups, medical societies and data scientists – with the goal of uncovering and addressing barriers that impede consistent MDT care in lung cancer.
This report provides recommendations for international, national and regional actors across three priority areas that seek to improve the timeliness and coordination of MDT care, and highlight areas in the lung cancer care pathway where the biggest impact for patients can be realised. These areas are:
- MDT review of treatment options/decisions
- Expertise represented on MDTs, including associated specialties
- MDT baseline and subsequent change
One recommendation in the report identifies the need to increase digital investment to overcome geographic barriers to MDTs meeting in person for both health care providers and patients. 78% of health care professionals believed that virtual MDTs would be the future of cancer care, and almost 92% thought MDTs would lead to global integration of specialists across treatment cases, according to a recent survey of 36 members of a sarcoma MDT.iii
David LeDuc, Associate Director, Oncology Patient Affairs, AstraZeneca, said, “One learning, among many, from the COVID-19 pandemic is that digital communication within health systems is not only valuable, but critical for more informed, effective and efficient care delivery. The use of virtual MDTs enables expertise to be delivered from varying locations, alleviating work force and patient pressures to attend physical appointments, ultimately illustrating an easier way for medical experts to convene.”
The report also explores how MDTs can not only shorten time between diagnosis and treatment, but how they can improve the quality and coordination of decisions made within that timeframe.
Andrew Duda, Director of Patient Advocacy – Oncology, Guardant Health, said, “Today, biomarker testing represents a critical tool that can enable health care professionals to identify the most appropriate treatment for a person’s cancer. Given the importance of these tests, it’s vital that MDTs work together to ensure that testing at diagnosis is delivered efficiently and effectively.”
The improvement of MDT access and coordination will take time and more careful analysis. Investment in infrastructure, by way of simple steps like annual audits and developing global guidelines for national MDT implementation, may aid this process. Establishing benchmarks for measuring effectiveness of treatment reviews, as well as ensuring appropriate representation of disciplines on tumour boards, will in time elevate MDT care to the place it needs to be to more consistently deliver optimal lung cancer care across treatment networks around the world.
i Lung Foundation Australia, Multidisciplinary Teams. Available at: https://lungfoundation.com.au/health-professionals/networks/multidisciplinary-teams/. Last Accessed June 2022
ii Walsh, J et. al.; BMC Health Serv Res. 2010; 10: 132. What are the current barriers to effective cancer care coordination? A qualitative study. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2891740/. Last Accessed June 2022
iii Will virtual multidisciplinary team meetings become the norm for musculoskeletal oncology care following the COVID-19 pandemic? - experience from a tertiary sarcoma centre. Available at: https://bmcmusculoskeletdisord.biomedcentral.com/articles/10.1186/s12891-020-03925-8. Accessed April 2022.
Date of Preparation: September 2022 | Document ID: Z4-48198